

FIVE-STAR STOCKS ★★★★★*Recommended by S&P equity analysts for superior total return potential over the next 12 months.*

SYM	COMPANY NAME	5 STARS SINCE	PRICE WHEN RECOMMENDED	CURRENT PRICE	COMMENT
ABT	Abbott Laborator	01/16/08	59.67	53.23	Confidence in earnings growth
ADSK	Autodesk Inc	02/28/08	33.11	29.90	Valuation
AEO	Amer Eagle Outfi	07/18/07	26.85	21.45	Valuation
AET	Aetna Inc	08/16/07	47.14	49.13	Valuation
AFL	AFLAC Inc	11/28/07	62.15	62.66	Top line growth, improving margins
AIB	Allied Irish Ban	12/11/07	47.8	40.68	Improved fundamental outlook
ALO	Alpharma Inc 'A'	03/04/08	25.01	25.30	Solid growth in new pain mgmt drugs
AMT	Amer Tower 'A'	01/11/08	39.03	37.63	Valuation
ANF	Abercrombie & Fi	09/20/05	45.96	78.65	Valuation
ARG	Airgas Inc	07/26/07	46.02	46.20	Benefits from cont'd strong demand
BBY	Best Buy	04/11/07	47.12	42.59	Valuation
BDX	Becton, Dickinso	01/24/08	87.17	90.52	Valuation
BHI	Baker Hughes	10/03/07	92.62	66.80	Trading at discount to competitor
BKC	Burger King	08/24/07	24.06	26.35	Valuation; see expansion
CB	Chubb Corp	03/08/06	47.75*	50.38	Valuation
CFR	Cullen/Frost Ban	11/01/06	53.8	50.74	Attractive valuation
CL	Colgate-Palmoliv	12/07/04	50.07	76.94	Benefits from restructuring plan
COH	Coach Inc	10/23/07	36.6	30.04	Valuation
COL	Rockwell Collins	01/22/08	58.06	57.66	Valuation
CSL	Carlisle Cos	06/07/06	40.08*	35.56	Valuation
CVD	Covance Inc	01/12/05	37.34	84.37	Valuation
CVLT	CommVault System	02/06/08	14.54	13.26	Valuation
CVS	CVS Caremark Cor	02/02/05	24.13*	40.91	Increased generic drug sales, valuation
CZN	Citizens Communi	06/08/07	15.3	10.96	Valuation
DIS	Disney (Walt) Co	11/10/06	32.4	31.87	Strong underlying trends
EBAY	eBay Inc	10/19/07	36.72	26.25	Valuation
EL	Lauder (Estee) C	12/14/07	43.3	43.28	Valuation
EMC	EMC Corp	12/13/07	19.18	15.36	Valuation
ETR	Entergy Corp	01/22/08	107.24	108.47	Valuation
FAST	Fastenal Co	07/12/07	46.42	40.48	Valuation, change in business model
FDX	FedEx Corp	12/21/05	103.7	90.31	Strong growth & margin improvement
FMC	FMC Corp	02/03/04	16.58*	57.16	Improving outlook
GENZ	Genzyme	01/25/08	73.67	73.63	Valuation
GLT	Glatfelter	05/10/06	17.71	13.33	Acquisitions; improving biz trends
GLW	Corning Inc	01/24/07	20.9	23.11	Stronger revenue growth

*Adjusted for stock split

Please see the Required Disclosures on the last page of this report.

<i>SYM</i>	<i>COMPANY NAME</i>	<i>5 STARS SINCE</i>	<i>PRICE WHEN RECOMMENDED</i>	<i>CURRENT PRICE</i>	<i>COMMENT</i>
GPI	Group 1 Automoti	07/31/07	37.52	24.40	Valuation
GR	Goodrich Corp	07/02/07	59.56	60.39	Continuing strength in aerospace orders
GRMN	Garmin Ltd	02/20/08	64.47	57.99	Valuation
GTXI	Gtx Inc.	01/28/08	11.09	15.25	Acapodene not as risky; deal w/MRK
HIG	Hartford Finl	08/05/05	77.15	69.64	See catalysts for growth
HNP	Huaneng Power In	02/04/08	36.25	31.39	Valuation
HOLX	Hologic Inc	05/31/07	54.02	57.45	Valuation, proposed merger with CYTC
HSC	Harsco Corp	07/26/07	54	56.27	Accelerating organic growth
IBM	Intl Bus. Machin	06/07/07	101.8	115.71	Valuation
ICLR	ICON Plc ADS	04/28/06	27.26*	68.13	Robust pharmaceutical, biotech pipeline
IM	Ingram Micro 'A'	01/24/08	16.95	15.46	Valuation
JEC	Jacobs Engr Grou	01/22/08	78.11	80.15	Further strength in oil & gas, refining
KMP	Kinder Morg Egy	08/23/07	50.83	57.62	Valuation
KO	Coca-Cola Co	12/17/07	62.47	59.37	High Intl exposure & acceleration
LH	Lab Corp	02/15/07	74.44	78.89	Sales growth, Blue Cross NJ contract
LOGI	Logitech Intl	12/12/07	35.29	24.69	Valuation
LYG	Lloyds TSB Group	06/08/07	45.47	35.60	Valuation
MAT	Mattel Inc	09/10/07	21.17	19.74	Valuation
MCD	McDonald's Corp	04/13/07	47.64	53.63	See better growth continuing
MCK	McKesson Corp	01/26/07	55.94	57.98	Healthy sales growth
ME	Mariner Energy	04/20/07	22.14	28.25	Valuation
MET	MetLife Inc	12/07/05	50.62	57.55	Valuation, improving underwriting mrgns
MFB	MaidenForm Brand	05/03/07	20.35	12.03	Valuation
MO	Altria Group	06/22/06	72.22	73.83	Valuation, improving litigation envrnmt
MR	Mindray Medical	10/19/07	39.79	35.36	Valuation, strong long term growth
MSFT	Microsoft Corp	06/07/07	29.62	27.59	Valuation
MTW	Manitowoc Compan	07/31/07	38.84*	40.25	Valuation
NE	Noble Corp	02/27/06	36.11	48.63	Rising jackup rig dayrates benefits
OKE	ONEOK Inc	12/11/07	45.82	47.30	Valuation
ORCL	Oracle Corp	12/14/06	18.02	18.44	Valuation
PAG	Penske Automotiv	07/31/07	19.48	17.91	Valuation
PETM	PETsMART Inc	02/01/08	23.98	21.92	Valuation
PG	Procter & Gamble	06/12/02	46.16*	66.05	Improving fundamentals
PSYS	Psychiatric Solu	07/26/07	36.47	30.05	Valuation
SBUX	Starbucks Corp	11/16/07	23.17	17.90	Compelling valuation
SFY	Swift Energy	03/27/06	37.97	46.75	Valuation
SJM	Smucker (J.M.)	12/14/07	50.08	51.38	Sharp P/E discount
SNDA	Shanda Interacti	09/19/07	33.33	32.79	Valuation
SPG	Simon Property G	03/07/07	107.33	85.65	Valuation
SPN	Superior Ene	05/22/06	29.99	40.55	See expanding business

**Adjusted for stock split*

<i>SYM</i>	<i>COMPANY NAME</i>	<i>5 STARS SINCE</i>	<i>PRICE WHEN RECOMMENDED</i>	<i>CURRENT PRICE</i>	<i>COMMENT</i>
STD	Banco Santander	10/30/07	21.41	17.71	Valuation
STO	Statoil ASA ADS	10/09/06	22.77	30.64	Valuation
STX	Seagate Technolo	07/20/07	24.63	22.91	Strong outlook with dominant mkt share
SWK	Stanley Works	10/24/07	58.05	48.84	Valuation
T	AT&T Inc	11/12/07	38.65	34.86	Increasing rev growth, valuation
TER	Teradyne Inc	12/13/07	10.46	12.20	Valuation
TEVA	Teva Pharm Indus	08/16/07	42.49	49.02	Favorable long term prospects
TEX	Terex Corp	10/19/07	81.52	66.00	Valuation, worldwide crane demand
TIF	Tiffany & Co	09/04/07	51.79	39.07	Valuation
TMO	Thermo Fisher Sc	05/08/06	38.54	54.98	Proposed acquisition of FSH
TOT	Total 'B' ADS	02/20/08	74.26	74.53	Valuation
TWC	Time Warner Cabl	02/06/08	23.65	27.62	Successful integration of acq'd systems
UA	Under Armour 'A'	01/17/08	37.06	36.30	Valuation
WFR	MEMC Electronic	09/10/07	57.92	78.22	Valuation
XOM	Exxon Mobil	02/01/08	85.95	86.69	Valuation

**Adjusted for stock split*

CHANGES LAST 5 DAYS

<i>DATE CHANGED</i>	<i>SYM</i>	<i>STOCK</i>	<i>NEW RANKING</i>	<i>OLD RANKING</i>	<i>REASON WHY</i>
3/4	ALO	Alpharma Inc 'A	☆☆☆☆☆	☆☆☆☆	Solid growth in new pain mgmt drugs
3/3	ACAS	Amer Capital St	☆☆☆☆	☆☆☆☆☆	Valuation
2/28	ADSK	Autodesk Inc	☆☆☆☆☆	☆☆☆☆	Valuation

Required Disclosures

March 4, 2008

S&P Global STARS Distribution

In the U.S.

As of September 30, 2007, research analysts at Standard & Poor's Equity Research Services U.S. recommended 34.1% of issuers with buy recommendations, 57.6% with hold recommendations and 8.3% with sell recommendations.

In Europe

As of September 30, 2007, research analysts at Standard & Poor's Equity Research Services Europe recommended 44.8% of issuers with buy recommendations, 36.0% with hold recommendations and 19.2% with sell recommendations.

In Asia

As of September 30, 2007, research analysts at Standard & Poor's Equity Research Services Asia recommended 45.5% of issuers with buy recommendations, 46.8% with hold recommendations and 7.7% with sell recommendations.

Globally

As of September 30, 2007, research analysts at Standard & Poor's Equity Research Services globally recommended 36.5% of issuers with buy recommendations, 53.7% with hold recommendations and 9.8% with sell recommendations.

5-STARS (Strong Buy): Total return is expected to outperform the total return of a relevant benchmark, by a wide margin over the coming 12 months, with shares rising in price on an absolute basis.

4-STARS (Buy): Total return is expected to outperform the total return of a relevant benchmark over the coming 12 months, with shares rising in price on an absolute basis.

3-STARS (Hold): Total return is expected to closely approximate the total return of a relevant benchmark over the coming 12 months, with shares generally rising in price on an absolute basis.

2-STARS (Sell): Total return is expected to underperform the total return of a relevant benchmark over the coming 12 months, and the share price is not anticipated to show a gain.

1-STARS (Strong Sell): Total return is expected to underperform the total return of a relevant benchmark by a wide margin over the coming 12 months, with shares falling in price on an absolute basis.

Relevant benchmarks: In the U.S. the relevant benchmark is the S&P 500 Index, in Europe and in Asia, the relevant benchmarks are generally the S&P Europe 350 Index and the S&P Asia 50 Index.

For All Regions:

All of the views expressed in this research report accurately reflect the research analyst's personal views regarding any and all of the subject securities or issuers. No part of analyst compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

Additional information is available upon request.

Other Disclosures

This report has been prepared and issued by Standard & Poor's and/or one of its affiliates. In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC ("SPIAS"). In the United States, research reports are issued by Standard & Poor's ("S&P"); in the United Kingdom by Standard & Poor's LLC ("S&P LLC"), which is authorized and regulated by the Financial Services Authority; in Hong Kong by Standard & Poor's LLC, which is regulated by the Hong Kong Securities Futures Commission; in Singapore by Standard & Poor's LLC, which is regulated by the Monetary Authority of Singapore; in Japan by Standard & Poor's LLC, which is regulated by the Kanto Financial Bureau; in Sweden by Standard & Poor's AB ("S&P AB"); in Malaysia by Standard & Poor's Malaysia Sdn Bhd ("S&P M"), which is regulated by the Securities Commission; in Australia by Standard & Poor's Information Services (Australia) Pty Ltd ("SPIS"), which is regulated by the Australian Securities & Investments Commission.

The research and analytical services performed by SPIAS, S&P LLC, S&P AB, S&P M, and SPIS are each conducted separately from any other analytical activity of Standard & Poor's.

For a list of companies mentioned in this report with whom S&P and/or one of its affiliates has had a business relationship within the past year, please go to <http://www2.standardandpoors.com/portal/site/sp/en/us/page.article/2,5,1,0,114,5719622102.html>

Disclaimers

This material is based upon information that we consider to be reliable, but neither S&P nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. With respect to reports issued by S&P LLC-Japan and in the case of inconsistencies between the English and Japanese version of a report, the English version prevails. Neither S&P LLC nor S&P guarantees the accuracy of the translation. Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Neither S&P nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

For residents of the U.K. -this report is only directed at and should only be relied on by persons outside of the United Kingdom or persons who are inside the United Kingdom and who have professional experience in matters relating to investments or who are high net worth persons, as defined in Article 19(5) or Article 49(2) (a) to (d) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001, respectively.

For residents of Malaysia, all queries in relation to this report should be referred to Alexander Chia, Lee Leng Hoe, or Ching Wah Tam.